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Abstract 
 
Medical management of cerebral palsy is a complex issue that should be undertaken 
with the overall aim to improve comfort, function in every day life, self confidence, 
participation and independence.  
Although the main focus is commonly the motor disorder, medical management also 
encompasses far wider issues including the management of multiple co-morbidities 
(e.g. epilepsy, visual and hearing impairment, gastro-oesophageal reflux and 
constipation, learning and behavioural difficulties) which require close multi-
disciplinary teamwork.  
High muscle tone can be broadly considered as either spasticity, dystonia, or 
commonly a mixed pattern. Strategies to reduce muscle tone include enteral 
medication, Botulinum neurotoxin, intra-thecal Baclofen, and selective dorsal 
rhizotomy. However, strength training and reduction of inserted involuntary 
movements are equally important strategies to improve function. 
We also discuss treatable conditions which mimic cerebral palsy, and explore 
potential future therapies such as stem cells. 
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Personal practice points: 
 
 All children with a new diagnosis of cerebral palsy should undergo brain 
imaging, ideally MRI scan 
 Although up to 20% of scans can be normal, this should prompt investigation 
for alternative causes, several of which can be treatable (including dopa 
responsive dystonia and GLUT 1 deficiency) 
 Invasive tone reduction therapies (e.g. botulinum neurotoxin, intra-thecal 
baclofen and selective dorsal rhizotomy) are increasingly available but should 
only be undertaken following detailed multi-disciplinary assessment and 
careful negotiation of goals and expectations with the child and family 
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Introduction ( level A heading) 
 
Cerebral palsy is a disorder of abnormal tone and posture arising from a non-
progressive abnormality of the infant brain. The majority of affected individuals will 
have increased muscle tone, although in a small minority tone may be normal or 
reduced. Variants of ataxic and hypotonic cerebral palsy are still recognised, although 
long term vigilance for progressive neurological disease is particularly important in 
these cases.   
Two main types of hypertonicity are recognised, i.e. spasticity and dystonia, although 
the two commonly co-exist. Both involve co-contraction of agonist and antagonistic 
muscle groups, but differ in important ways. Spasticity is defined as a velocity 
dependent increase in muscle tone, which leads to clinical signs including a spastic 
“catch”, clonus and brisk deep tendon jerk reflexes. Dystonia is more fluctuant, not 
velocity dependent, and more likely to lead to twisting postures. 
The majority of currently available medical therapies are directed at tone reduction, 
but it is vital to emphasise that hypertonicity is just one aspect of the upper motor 
neuron syndrome, and that in many children the other associated features of poor 
motor control or weakness are a greater barrier to function. Great care must be 
exercised in strategies to reduce muscle tone (particularly in irreversible procedures 
such as selective dorsal rhizotomy), as some children are reliant on spasticity to 
functionally compensate for major underlying weakness. In this situation spasticity 
reduction can lead to an unwelcome reduction in functional performance.  
Strategies to improve function, reduce pain, and therefore improve quality of life in 
young people with cerebral palsy can include:  
 Tone reduction to reduce contractures, postural deformity, and discomfort 
 Strength training to improve weakness 
 Improve co-ordination by better motor control or reduction of involuntary 
inserted movements 
 
It is vital to emphasise that medical management should always be in the context of 
input from a multi-disciplinary team. For example, tone reduction without 
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physiotherapy is almost always futile. The above strategies must also be placed within 
the wider context of management of the associated co-morbidities of cerebral palsy, 
which commonly include complex multi-organ pathology (see table 1). 
 
INSERT TABLE 1 
 
Assessment (A) 
 
Before undertaking any interventions it is essential to perform a detailed baseline 
physical assessment, including: 
 Assessment of tone – the modified Ashworth score is a useful tool to quantify 
the degree of spasticity in individual muscles. In subjects with predominant 
dystonia this can be quantified with tools such as the Burke-Fahn-Marsden, 
Barry-Albright or Dyskinesia Rating Scale. Where spasticity and dystonia 
appear to co-exist the Hypertonia Assessment Scale can be considered. 
 Careful documentation of fixed contractures (sometimes examination under 
anaesthetic is very helpful) 
 Assessment of power (e.g. using the MRC 5 point scale) 
 Documentation of functional levels. If time permits the gross motor function 
measure (GMFM) is a well validated detailed assessment tool able to 
demonstrate even relatively small changes in function. In a busy clinic the 
gross motor function classification score (GMFCS) is a quick and useful 
guide to level of mobility, as is the manual ability classification score 
(MACS) for upper limb function. Gait analysis where available is very 
helpful, and should be strongly considered if orthopaedic or neurosurgery is 
contemplated. 
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Neurological Investigations  (A) 
 
Imaging of the brain should be performed in all suspected cases of cerebral palsy. 
Rarely a space occupying lesion will be discovered that requires urgent neurosurgical 
assessment (e.g. a brain tumour, or arachnoid cyst obstructing CSF flow causing 
hydrocephalus). Although as many as 20% of children with cerebral palsy are known 
to have normal imaging, it should nevertheless raise clinical suspicion of the 
possibility of an alternative diagnosis, some of which are treatable, including: 
 Tethered spinal cord 
 Segawa syndrome (also known as dopa-responsive dystonia). Although rare 
this is an important condition not to miss as the motor symptoms are fully 
reversible with low dose L-dopa.  
 GLUT1 deficiency. This is a disorder of brain energy metabolism due to 
impaired glucose transport into the brain. It can present with seizures, 
persistent/paroxysmal movement disorders, gait abnormalities and motor 
developmental delay. Diagnosis can be achieved by either demonstration of a 
low CSF to plasma glucose concentration (typically less than 0.4, although 
higher ratios are reported) and mutation analysis of the SLC2A1 gene. The 
ketogenic diet can be helpful in both epilepsy and movement disorders due to 
GLUT1 deficiency. 
 Metabolic disease including glutaric aciduria type 1, biotinidase deficiency, 
mitochondrial disease 
 Single gene disorders such as hereditary spastic paraparesis (although onset is 
only rarely in infancy) 
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Conventional medical therapies to reduce hypertonicity (A) 
 
Conventional medical therapies to reduce spasticity and/or dystonia can be targeted in 
4 main ways: 
1. Direct muscle relaxants 
2. Denervation or neuromuscular blockade 
3. Central inhibition 
4. Reduction of afferent input from the hypersensitive stretch reflex by selective 
dorsal rhizotomy  
Alternatively they can be considered via their route of administration e.g. enteral 
medications (see table 2), localised injections (e.g. botulinum neurotoxin), or more 
general measures (e.g. intra-thecal baclofen or selective dorsal rhizotomy). 
 
1. Direct muscle relaxants (level B heading) 
 
Dantrolene inhibits calcium release from the sarcoplasmic reticulum of muscle cells. 
Although generally safe, there are reports of dantrolene associated hepatitis in adults, 
and therefore it is recommended that liver function tests are monitored prior to and at 
intervals after starting therapy. 
 
2. Denervation or neuromuscular blockade (B) 
 
Chemical denervation can be achieved using either Botulinum neurotoxin (BoNT) or 
Phenol. BoNT has been in widespread use for over 20 years. In addition to tone 
reduction, it is also used in cerebral palsy to reduce drooling and correction of 
strabismus. 
The majority of medical use is type A toxin (BoNT-A), which is composed of a heavy 
and light chain. The light chain interferes with the binding and release of 
acetylcholine across the muscle junction, thereby resulting in weakness due to 
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chemical denervation. The effect usually lasts 3-4 months, until reinnervation occurs 
due to progressive nerve sprouting.  
The two major drawbacks to BoNT-A are the short term duration of effect, and the 
need for it to be administered by injection, usually into multiple muscle groups. The 
majority of injections for children in the UK are performed under sedation (e.g. 
Midazolam), or with inhaled nitrous oxide. General anaesthesia still has a role, and 
has the additional advantage of allowing a detailed assessment of fixed contractures. 
Most experts agree on the need for accurate localisation of the muscle. Large muscles 
(e.g. gatrocnemius) can usually be safely identified on anatomical grounds, but 
injection of small or deep seated muscles is aided by nerve stimulator or ultrasound 
guidance. Some experts also stress the need to inject as near to the motor end plate as 
possible, although others argue that the inevitable diffusion throughout the injected 
(and adjacent) muscles renders this non-essential. 
There are several different commercially available preparations of BoNT-A available 
in the UK. Differences are claimed by the manufacturers in relation to the degree of 
protein binding (which may affect the extent of diffusion to adjacent or more 
widespread muscle groups), but the main thing to highlight to the novice is that the 
dosage in units per kg varies between the two most widely used products (Botox® and 
Dysport®). A precise comparison is not published, but as a general guide most 
clinicians consider a ratio of between 2-3 units of Dysport® to 1 unit of Botox®.  
Theoretical concerns about BoNT-A include the long term effect on muscle 
architecture, and there is some data derived from animal experiments demonstrating 
the potential for retrograde transmission into the CNS. However, the safety record of 
BoNT-A in clinical practice is remarkably good, although transient unwanted effects 
are not uncommon (e.g. pain at injection site, flu like symptoms, weakness). The more 
serious side effects include an association with dysphagia (more likely after head or 
neck injections), and a small increase in chest infections. The more serious side 
effects are more common in children with the greatest degree of physical impairment, 
and when higher doses are used. As a consequence many clinicians are now cautious 
in using very  high doses in severe neurodisability.   
There are now a large number of publications demonstrating relatively short term 
reduction in muscle tone leading to increased range of joint movement and/or 
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improved ambulation, but very limited data on long term benefits in gait or upper 
limb function. 
 
3. Central inhibition (B) 
 
Enteral administered medication (level C heading) 
Enteral therapies to reduce muscle tone due to spasticity and/or dystonia by central 
inhibition are summarised in table 2.  
 
INSERT TABLE 2 
 
Baclofen is an agonist of GABA, an inhibitory neurotransmitter, with purported effect 
at both spinal interneurons and within the brain. Double blind trials have shown clear 
evidence of spasticity reduction in adults, although benefit is often modest from oral 
use and unwanted effects common. These can include fatigue, drowsiness, or loss of 
function due to weakness e.g. loss of head control. 
Diazepam is believed to have muscle relaxant and a central inhibitory effect on 
muscle tone, via GABA-A receptors. It also has an anxiolytic effect. Sedation is a 
concern, although provided it is started at a low dose and increased gradually serious 
short term side effects are uncommon. There are however concerns about long term 
dependency in adults. Diazepam is therefore best used for short courses, or in children 
with a significantly reduced life expectancy who experience frequent distressing 
symptoms. If withdrawn after long term use it should always be weaned over a 
prolonged period of many months. 
Tizanidine acts centrally via alpha-2 adrenergic receptors. It is licensed for use in 
adults with multiple sclerosis, but can be used in children with caution. Monitoring of 
liver function is necessary. 
Gabapentin was initially developed for use in epilepsy, but is also effective in 
neuropathic pain, and there are case reports of benefit in spasticity reduction. 
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Trihexiphenidyl is an anti-cholinergic therapy that is often effective in both primary 
and secondary dystonia. It has little effect on spasticity. The mechanism of action is 
believed to be central. Side effects are predictable and dose related, including dry 
mouth, constipation, urinary retention, and blurred vision. They are reversible on 
discontinuing medication. 
L-dopa (L-3,4-dihydroxyphenylalanine) is the precursor of the neurotransmitter 
dopamine is the amino acid precursor of dopamine.  Doses of L-dopa as low as 
0.5mg/kg three times daily are sufficient to produce a dramatic response in Segawa 
syndrome, although other neurotransmitter disorders (e.g. the pterin defects and 
tyrosine hydroxylase deficiency) may require higher doses  of between 3 and 10 
mg/kg three times daily. Response in secondary dystonia is often minimal and 
therefore L-dopa is often used only for short term trials unless there is a striking 
improvement. L-dopa is given in a combined preparation with a peripheral dopa-
decarboxylase inhibitor which reduces the systemic side effects, commonly nausea, 
vomiting or postural hypotension.  Domperidone can also be used if nausea is 
particularly problematic. Rarely L-dopa will exacerbate dyskinetic movements.  
 
Intra-thecal Baclofen (ITB) (C) 
 
Although Baclofen is rapidly absorbed following oral administration it has relatively 
poor lipid solubility and only limited penetration into the central nervous system. 
Efficacy is dramatically improved by intra-thecal (or intra-ventricular) delivery which 
bypasses the blood brain barrier. Doses used are typically less than 1% of the enteral 
equivalent, often between 200 to 800 micrograms per day. Most commonly this is 
delivered at a continuous steady rate which can be adjusted by an external 
programmer. 
The clear indication for ITB is in non-ambulant children with severe spasticity. This 
has been shown to improve comfort and ease of care. Intuitively it might also be 
expected to reduce the rate of hip migration although this is not yet confirmed. The 
effect on progression of scoliosis is more unpredictable. ITB is also potentially 
attractive in ambulant children as an alternative to selective dorsal rhizotomy. It has 
the advantages of being reversible, and titratable, and would therefore be more 
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appropriate in children with progressive illnesses, significant co-existent dystonia, and 
those in whom there is concern about underlying weakness. However, current 
experience in ambulant children is limited and inconclusive. 
Pre-surgical evaluation should always include a detailed assessment as above, and in 
most centres a test dose in strongly recommended. Although rare, there do appear a 
small minority (approximately 5%) of non-responders to a test dose in whom 
proceeding to implantation will be at best disappointing. The test dose is commonly 
delivered as a single intra-thecal bolus of 50 micrograms, followed by careful medical 
and physiotherapy assessment at around 4 hours later. Some centres insert a 
temporary catheter to allow titrated infusions over several days, which may be helpful 
particularly in secondary dystonia where a delayed effect and higher dose 
requirements are expected. Opinion is divided between implanting surgeons on the 
optimal position for the catheter tip. A more rostral position may give more 
widespread tone reduction, although there is inevitably considerable diffusion 
throughout the CSF space. 
The inevitable down side of ITB pumps is the need for regular refills, typically 3-4 
times per year. This involves direct access of the pump via a percutaneous needle. 
Also in the current generation of pumps the battery tends to last no more than 7 years 
at which point the entire device needs to be replaced. Reported side effects include 
infection (occasionally necessitating removal of the device), pump failure (very rare), 
and catheter disconnection or fracture (not uncommon). The latter two complications 
can trigger marked rebound spasticity, which can be potentially very serious in a 
fragile child with complex severe neurodisability. Families should therefore be given 
a prescription for oral Baclofen to keep in their emergency drug cupboard for this 
eventuality. Drug overdose can also potentially lead to respiratory impairment.  
 
Deep brain stimulation (A) 
 
Deep brain stimulation (DBS) is increasingly offered to adults with Parkinsons 
disease, and also widely accepted as first line treatment for primary generalised 
dystonia in adults and children, many of whom return to normal levels of daily 
activity. The usual target for electrode placement is bilateral globus pallidus internus. 
 12 
The benefit in secondary dystonia is less dramatic, but there are small case series and 
case reports describing benefit in certain sub-groups, including children with 
pantothenate-kinase associated neurodegeneration (PKAN) and dystonic cerebral 
palsy following hypoxic-ischaemic injury to the basal ganglia. Further research is 
required before this can be considered routine practice.  
 
Therapies to improve motor control (A) 
 
Therapies to improve motor control can be considered in two broad groups: 
a) Strategies to reduce unwanted (negative) movements  
b) Strategies to improve positive features of motor performance (e.g. strength and 
control) 
 
Enteral medications to reduce unwanted dyskinetic movements include 
Tetrabenazine, Levetiracetam, Piracetam, Carbamazepine, and Sodium Valproate. 
Orthoses have a valuable role to play in motor control and the expert advice of 
physiotherapists and orthotists is invaluable in obtaining the right prescription. 
Second skin garments (such as lycra suits) have particular interest in the management 
of dystonia, as aberrant sensory feedback is a significant contributor to the generation 
of dystonic movements. 
Historically there was a school of thought that discouraged strength training due to 
concerns that it may exacerbate spasticity. However, there is now good evidence that 
this anxiety is unfounded, and strength training and exercise has a valuable role in 
improving function. This can be delivered by exercise programs, and/or in 
conjunction with functional electrical stimulation. 
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Unconventional or experimental medical therapies (A) 
 
Many unconventional physical and medical therapies have been offered to children 
with cerebral palsy. They include special diets, horse riding (hippotherapy) hyperbaric 
oxygen, and acupuncture, to name but a few. Whilst some of these will almost 
certainly have additional holistic benefits on quality of life, there is no convincing 
evidence of functional improvement. 
  
Therapies to encourage or modify brain plasticity (A) 
 
The ability of the developing brain to reorganise (so called brain plasticity) is often 
quoted as an illustration of the potential for recovery from brain injury by relocation 
of important cortical functions. Positive examples include the relocation of language 
skills to the non-dominant hemisphere, and experiments showing that in children born 
blind the occipital cortex (normally responsible for vision) is integral to Braille 
reading skills. However, not all brain plasticity is positive and there is some evidence 
following neonatal stroke that when the unaffected hemisphere develops dominance 
of control over the paretic limb that this is associated with a poor outcome. The early 
use (under 12 months) of constraint induced movement therapy in unilateral cerebral 
palsy to modify brain plasticity remains contentious.  
 
Stem cell transplantation (A) 
 
A common question asked of clinicians working with children with cerebral palsy is 
whether there is role for stem cells to cure or improve the condition. The use of 
embryonic human tissue remains highly controversial, but cord blood is another 
source of embryonic stem cells with far less ethical concerns. Recent advances 
allowing the transformation of human fibroblasts into induced pluripotent stem cells 
(and further differentiation into specific types of  neurons) are also promising. 
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In theory the undifferentiated stem cells delivered (by intra-thecal or intra-ventricular 
injection) into an area of early brain injury might be able to allow regeneration of the 
injured area. This is intuitively attractive for lesions such as peri-ventricular 
leucomalacia where the motor cortex may not be directly injured. There is some 
evidence in murine and primate  models this could be feasible, there are several large 
clinical trials ongoing, and the procedure is now available in China and certain centres 
in Europe. Nevertheless, at present there is an absence of peer reviewed evidence to 
support its effectiveness and safety in human subjects, and the authors current practice 
is to advise caution to parents in this situation.   
 
Case study 1 
A 6 year old girl is referred for a second opinion on the diagnosis of cerebral palsy. 
She was born at term with a normal birth history. Brain MRI is normal. Muscle tone is 
increased in the lower limbs with brisk reflexes, although downgoing plantar 
responses. She can walk 10 metres with support, but not unaided. The diagnosis is 
suggested when her parents ask “why doesn’t she have cerebral palsy in the morning 
doctor?” 
Normal brain imaging is compatible with a diagnosis of cerebral palsy, but should 
always raise concern, particularly if there is an uneventful pregnancy and birth 
history. Dopa responsive dystonia (Segawa syndrome) is a rare but important mimic 
of cerebral palsy. It is due to an enzyme deficiency in the generation of 
tetrahydrobiopterin which is an essential co-factor for the production of Dopamine. 
Diurnal variation is an important clue, but even when absent clinicians should have a 
low threshold for an empirical trial of low dose L-dopa. The improvement in usually 
rapid (within 24 hours) and dramatic. This young lady was walking unaided within a 
few days, and retains normal mobility at age 16 years. The diagnosis can be 
confirmed on genetic testing (GCH1 gene) and/or CSF neurotransmitter analysis.  
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Case study 2 
A 3 year old boy with bilateral lower limb spasticity is referred for evaluation for 
selective dorsal rhizotomy. He is an ex-premature infant (born at 28 weeks gestation) 
and his MRI brain scan shows peri-ventricular leucomalacia. He has begun walking 
with a frame in the last 6 months (GMFCS level III). He has moderate to severe lower 
limb spasticity, minimal upper limb involvement, and appears strong with good motor 
control. 
He was considered a good candidate for SDR. However, he is still making ongoing 
functional progress at this age. Reassessment was recommended after age 4 years 
when he will have begun to plateau in his acquisition of motor skills. In the meantime 
he continues with 6 monthly Botulinum toxin injections to preserve joint range of 
movement. 
 
Case study 3 
A 10 year old girl is also referred for evaluation for selective dorsal rhizotomy. She 
developed cerebral palsy as a consequence of group B streptococcal meningitis in the 
neonatal period. She has severe bilateral spasticity, and is wheelchair dependent 
(GMFCS level V). She also has severe  learning difficulties. Her parents would like 
her to walk.  
After counselling and education of the various options parents accepted SDR was not 
likely to lead to walking ability. However, they accepted referral for implantation of 
an intra-thecal Baclofen pump to improve their daughter’s comfort and ease of care.  
 
Case study 4 
An 8 year old girl with a diagnosis of cerebral palsy is referred for assessment as her 
condition is worsening. She diagnosed in infancy with hypotonic cerebral palsy 
walking at age 3 years. However, her gait now appears a combination of spasticity 
and ataxia.  
A diagnosis of GLUT1 deficiency was suspected based on normal brain imaging, and 
the history of improvement following meals. Fasted CSF to plasma glucose ratio was 
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0.33, and subsequently a mutation in the SLC2A1 gene was confirmed. Her symptoms 
improved on the ketogenic diet. 
 
 
Conclusion           
 
In the last two decades there have been considerable advances in the medical 
management of  cerebral palsy. The majority of these therapeutic options are currently 
directed towards tone reduction with the aim to improve range of joint motion, the 
prevention of postural deformity, improvement of function, and/or improve comfort 
and ease of care. Function can also be improved by strength training, and strategies to 
improve motor control. 
Further advances, including stem cell therapy, are eagerly awaited although as yet 
unproven. 
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Table 1 
 
Associated co-morbidities of cerebral palsy 
  
Neurological Epilepsy, hydrocephalus, visual and hearing impairment 
Behavioural and 
learning 
Sleep disturbance, depression, autistic features, learning 
difficulties, vulnerability 
Gastro-intestinal Difficulty swallowing, gastro-oesophageal reflux, constipation 
Bone Osteoporosis, scoliosis, hip dislocation, pathological fractures 
Respiratory Susceptibility to chest infections and aspiration 
Skin Drooling, pressure sores 
Dental Poor oral hygiene, susceptibility to dental caries 
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Table 2 
 
Personal practice of authors for oral medications to treat abnormal tone, posture 
and inserted movements in children with cerebral palsy 
 
 Spasticity Dystonia Dyskinetic 
movements 
First line Baclofen Trihexiphenidyl 
Gabapentin 
Clonidine 
L-dopa (first line if 
considering 
Segawa syndrome) 
Levetiracetam 
Second line Gabapentin  
Diazepam 
Baclofen 
Diazepam  
 
Tetrabenazine 
Sodium Valproate 
Carbamazepine 
Third line Dantrolene 
Tizanidine 
 
Carbamazepine 
(particularly 
helpful in PKD) 
Dantrolene 
Gabapentin 
Clonidine 
Diazepam 
 
Abbreviation: 
PKD Paroxysmal kinesogenic dystonia 
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